ACETAZOLAMIDE SODIUM

Post-LOE

acetazolamide sodium

Viatris (2)

ANDAINJECTIONINJECTABLE

Approved

May 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ACETAZOLAMIDE SODIUM (acetazolamide sodium) by Viatris (2) is clinical pharmacology acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e. Approved for heart failure, glaucoma. First approved in 2012.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g., some types of glaucoma), in the treatment of certain convulsive disorders (e.g., epilepsy) and in the promotion of diuresis in instances of abnormal fluid retention…

Worked on ACETAZOLAMIDE SODIUM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ACETAZOLAMIDE SODIUM

Mechanism of Action

Indications (2)